In many cancers, particularly those driven by hyperactive kinase signaling, such as NSCLC [241], SOC [242], AML [102], and breast cancer [6], PP2A predominantly functions as a tumor suppressor. This evidence concerns the gene PTPA and acute myeloid leukemia.